Coram to Purchase Caremark's Home Infusion Therapy Business

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 3
Volume 4
Issue 3

DENVER--Coram Healthcare Corp. has reached a definitive agreement to acquire Caremark International's home infusion therapy business. Under the agreement, Caremark will receive approximately $310 million in cash and securities.

DENVER--Coram Healthcare Corp. has reached a definitive agreementto acquire Caremark International's home infusion therapy business.Under the agreement, Caremark will receive approximately $310million in cash and securities.

Articles in this issue
Selecting a Support Group for Patients With Prostate Carcinoma
Antman Provides Outlook on Use of High-Dose Chemo
Radiofrequency Ablation of Brain Tumors New Option
Oncologist Enthusiastic About Capitated Plan
Digital Mammography Has Potential to Detect Small Tumors, Increase Accuracy in Dense Breasts
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Varmins Chooses New Director for NIH Office of Alternative Medicine
Identifying the 'Sentinel' Lymph Node May Obviate Need for Total Axillary Dissection
'Visible Man' Hits the Internet, Radiologists Get the First Look
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, Kids
WHO Melanoma Study: Interferon Boosts Disease-Free Survival
Coram to Purchase Caremark's Home Infusion Therapy Business
NCCR Unveils Six New Public Service TV Announcements
GAO Says Federal Research Needed on Safety of Portable Cellular Telephones
Breast Examination Center of Harlem Expands Service
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content
Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy

Russ Conroy
November 27th 2025
Article

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.

Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma

Roman Fabbricatore
November 26th 2025
Article

The regulatory decision was supported by findings from the phase 1/2 BGB-11417-201 trial, which evaluated sonrotoclax monotherapy in those with MCL.

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

Ariana Pelosci
November 26th 2025
Article

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.